How NewLimit Compares to Other Anti-Aging Startups

Most people writing about anti-aging biotech have never had to make a single hard scientific decision, never stared down a failed experiment at 11pm, and never tried to convince an investor that reprogramming a cell can actually work. So when you read polished corporate comparisons of these companies, take them with a grain of salt.

Here is a real look at how NewLimit sits against its rivals. No fluff. Just facts, context, and a few things the press release version tends to leave out.

NewLimit was founded in 2021 by Coinbase CEO Brian Armstrong, bioengineer Blake Byers, and computational biologist Jacob Kimmel. The company is based in South San Francisco, and its mission is simple to say, brutally hard to execute: reprogram aging cells to act young again. By June 2026, it had raised $435 million in a Series C led by Founders Fund, putting its valuation at roughly $3.1 billion. That kind of number gets people’s attention. But the real story is not the valuation. It is what they have actually built and how that compares to the other big players swinging at the same problem.

NewLimit vs. Altos Labs: Which Anti-Aging Startup Is More Advanced?

Start with Altos Labs, because everyone does. And with good reason. Altos launched in 2022 with $3 billion. Not raised over time. At launch. Jeff Bezos and Yuri Milner were reportedly among the backers. Four Nobel laureates joined the team. Research institutes in the US and UK. The thing was built to look like the Apollo Program of aging science.

And yet. Here is the kicker.

Altos Labs has said almost nothing publicly about its actual science or pipeline. No clinic-ready candidates announced. No imminent human trials. The strategy appears to be: go deep on the fundamental biology of cellular rejuvenation, map everything, and then figure out which drugs to build. It is a long game. A very expensive long game.

NewLimit took a completely different bet. Focus on one organ. One disease. Move fast. By December 2025, the company had already identified three prototype medicines capable of reprogramming liver cells to restore youthful function. In June 2026, it announced plans to file for its first clinical trial in 2027, targeting alcohol-induced liver disease.

So which is more advanced? On paper, Altos has more money and more Nobel laureates. In practice, NewLimit is closer to actually treating a human patient. That gap is significant. NewLimit got to a $3.1 billion valuation on a fraction of Altos’s capital. Call it efficiency. Call it focus. Either way, it matters.

NewLimit vs. Retro Biosciences: Different Approaches to Fighting Aging

Retro Biosciences came out of stealth in 2022 with $180 million in backing from Sam Altman. The mission: add 10 healthy years to the average human lifespan by 2030. Bold target. No apologies for the ambition.

But the biology Retro is using looks quite different from what NewLimit is doing.

Retro’s core strategy pulls from multiple directions at once. It works on hematopoietic stem cell reprogramming, autophagy enhancement (think of it as the body’s internal cellular recycling system), and plasma-derived therapies. In late 2025, Retro actually entered human trials with RTR242, a pill designed to boost autophagy and target Alzheimer’s disease. And in August 2025, working alongside OpenAI, the company announced that its AI models had made cellular reprogramming 50 times more efficient. By early 2026, Retro was reportedly working toward a $1 billion Series A at a $5 billion valuation.

That is genuinely impressive. Retro is already in a human trial. NewLimit is not. Yet.

But here is what NewLimit is doing instead. It picked a single delivery method: mRNA inside lipid nanoparticles, sent directly to liver cells. Those cells then express transcription factors that make them act younger. The company screened over 3,000 transcription factor combinations. More than 20 sets showed the ability to rejuvenate both hepatocytes and T cells. Every experiment feeds back into an AI model that sharpens the next round of choices.

The honest read: Retro has a clinical head start. NewLimit has a tighter, more replicable platform. Both are serious. Both could work. The approaches just reflect fundamentally different philosophies about how to take on aging biology.

How NewLimit’s AI Technology Sets It Apart from Competitors

This is the part that does not get enough attention in the usual coverage.

Most biotech companies, even well-funded ones, still run drug discovery the old-fashioned way. You form a hypothesis. You run a physical experiment. You wait. You analyze. You repeat, thousands of times, across years. It is slow. It is expensive. And most experiments fail.

NewLimit built something different. Its AI model simulates experiments before anyone touches a pipette. The company runs the most promising candidates in a real lab, collects the data, and feeds it straight back into the model to make it smarter. They call this “lab in a loop.” It sounds simple. The execution is not.

The result is that NewLimit can move at a pace that its headcount should not allow. As of 2026, the company has roughly 40 to 50 employees. And it has advanced a drug candidate to the edge of clinical trials. Most biotech companies with that headcount are still figuring out their research direction.

Compare that to the broader field. Altos Labs has not publicly built an equivalent AI-first discovery platform at its core. Retro Biosciences brought in OpenAI as a partner in 2025 to improve its reprogramming factors, which is meaningful. But from what has been reported, that integration came later and is not the engine driving every experiment the way it is at NewLimit.

And this is the thing about capital efficiency. From 2021 through mid-2026, NewLimit raised approximately $760 million total, at a pace of around $169 million per year. Altos raised $3 billion before reaching a similar level of clinical clarity. That gap tells you something real about what the AI platform is actually worth in practice.

Who Has Raised More Money: NewLimit or Its Rivals?

The numbers are not close if you just look at totals.

Altos Labs: $3 billion, raised at launch in 2022. Full stop. No other private longevity company touches that number.

Retro Biosciences started with $180 million from Sam Altman and by early 2026 was reportedly targeting a $1 billion Series A at a $5 billion valuation. That puts its total raised well above $1 billion.

Life Biosciences, co-founded by Harvard geneticist David Sinclair, raised $80 million in early 2026. Smaller number. But they were first to receive FDA clearance for a human trial of partial epigenetic reprogramming. That is not a small thing.

Now look at NewLimit’s trajectory. Series A of $40 million in 2023. Series B of $130 million in May 2025. An additional $45 million in October 2025. Then the Series C of $435 million in June 2026, led by Founders Fund, with Thrive Capital, Eli Lilly Ventures, Kleiner Perkins, and Greenoaks Capital all joining in. Total cumulative funding: approximately $760 million.

Here is what that trajectory actually shows. The jump from Series B to Series C was more than 3x in just 13 months. That kind of acceleration does not happen by accident. Investors saw something in the data, in the liver cell results, in the AI platform’s performance. They moved.

The reality is, NewLimit is not the best-funded anti-aging startup. Not by a long shot. But it is closing in on a $3.1 billion valuation while spending its capital with a discipline that most of its rivals have not matched. And in this field, where plenty of well-funded companies have failed to make it to human trials, being smart with money matters at least as much as having a lot of it.

So the question is not just who raised more. The question is who is turning that money into medicine. On that front, the race is genuinely still open.

The anti-aging startup space is full of big promises and bigger checks. Most of these companies will not make it. Some will. And the ones that do will probably be the ones that stayed focused when everyone else tried to do everything at once. That is what makes NewLimit worth watching. Not the valuation. Not the famous co-founder. The discipline. The data. And the very real possibility that a reprogrammed liver cell in a lab in South San Francisco today becomes a treatment that changes lives in a decade.

NewLimit Raised $435M

NewLimit’s AI Technology: How It Discovers Anti-Aging Medicines